Akay Olga Meltem, Aras Beyhan Durak, Isiksoy Serap, Toprak Cigdem, Mutlu Fezan Sahin, Artan Sevilhan, Oner Ulku, Gulbas Zafer
Department of Hematology, Eskisehir Osmangazi University Medical School, Eskisehir, Turkey.
Department of Medical Genetics, Eskisehir Osmangazi University Medical School, Eskisehir, Turkey.
Cancer Genet. 2014 Mar;207(3):87-93. doi: 10.1016/j.cancergen.2014.02.001. Epub 2014 Feb 8.
The purpose of this study was to determine the frequency of BCL2, BCL6, IGH, TP53, and MYC protein expression and rearrangements of the respective genes in diffuse large B-cell lymphoma (DLBCL) patients and to assess their prognostic values. Samples from 44 patients with DLBCL were evaluated using fluorescence in situ hybridization and immunohistochemical analyses. BCL6 was the most rearranged gene (63.6%), followed by MYC (31.8%), TP53 (22.7%), and BCL2 (18.2%). Multiple rearrangements were detected in 40.9% of the cases. BCL6 was the most expressed protein (78.6%), followed by TP53 (69.04%), BCL2 (59.5%) and MYC (14.3%). Expression of multiple proteins was detected in 67.4% of the cases. BCL2 (P = .003) expression had a significant negative influence on overall survival,whereas BCL6 (P = .014) expression had a significant positive influence. Our results with a different pattern of gene rearrangements and associated protein overexpression indicate the molecular genetic complexity of DLBCLs, which reflects the morphologic, biologic, and clinical heterogeneity of these lymphomas.
本研究的目的是确定弥漫性大B细胞淋巴瘤（DLBCL）患者中BCL2、BCL6、IGH、TP53和MYC蛋白表达的频率以及各基因的重排情况，并评估其预后价值。使用荧光原位杂交和免疫组织化学分析对44例DLBCL患者的样本进行评估。BCL6是重排最多的基因（63.6%），其次是MYC（31.8%）、TP53（22.7%）和BCL2（18.2%）。40.9%的病例检测到多重重排。BCL6是表达最多的蛋白（78.6%），其次是TP53（69.04%）、BCL2（59.5%）和MYC（14.3%）。67.4%的病例检测到多种蛋白表达。BCL2（P = .003）表达对总生存期有显著负面影响，而BCL6（P = .014）表达有显著正面影响。我们关于基因重排和相关蛋白过表达的不同模式的结果表明了DLBCL的分子遗传复杂性，这反映了这些淋巴瘤在形态学、生物学和临床方面的异质性。
